JPS58216122A - Nutrient product for infant of histidinemia - Google Patents
Nutrient product for infant of histidinemiaInfo
- Publication number
- JPS58216122A JPS58216122A JP57098516A JP9851682A JPS58216122A JP S58216122 A JPS58216122 A JP S58216122A JP 57098516 A JP57098516 A JP 57098516A JP 9851682 A JP9851682 A JP 9851682A JP S58216122 A JPS58216122 A JP S58216122A
- Authority
- JP
- Japan
- Prior art keywords
- product
- infants
- histidine
- histidinemia
- vitamins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Seeds, Soups, And Other Foods (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は、ヒスチジン血症の乳幼児の治療及び栄養供給
を目的とした乳幼児用栄養調製物に関するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an infant nutritional preparation intended for the treatment and nutrition of infants with histidinemia.
更に詳細には、本発明は、消化吸収の極めて優れたヒス
チジン血症乳幼児用栄養調製物に関するものである。More specifically, the present invention relates to a nutritional preparation for histidinemic infants that is highly digestible and absorbable.
一般に、ヒスチジン血症はアミノ酸代謝異常症の一種で
、ヒスチダーゼ作用の欠如によって、ヒュf’;775
、らつ。カー:/11!へ。代謝ヵ;阻害さn−’r、
血φのヒスチジン量が異常に増加する遺祖的症状をいう
。In general, histidinemia is a type of amino acid metabolic disorder, and is caused by the lack of histidase activity.
, Ratsu. Car: /11! fart. Metabolism; inhibited;
It is an inherited symptom in which the amount of histidine in blood φ increases abnormally.
ヒスチジン血症乳幼児に卦いそは、血中にヒスチジン量
を増加させてはならず、そのために、従来は、アミノ酸
を低ヒスチジンになるように組合せたアミノ酸製剤が用
いられていた。For infants and infants with histidinemia, the amount of histidine in the blood must not be increased, and for this reason, amino acid preparations have been conventionally used in which amino acids are combined to have low histidine levels.
しかしながら、アミノ酸製剤では、アミノ酸特有の異臭
や苦味があり経口投与では乳幼児がいやがり飲まないと
いう問題があった。However, amino acid preparations have a problem in that infants are reluctant to drink them when administered orally due to the unusual odor and bitterness characteristic of amino acids.
本発明者らは、飲みやすくしたヒスチジン血症乳幼児用
栄養調製物を求めて研究した結果、自然の牛乳ホエー蛋
白質とアミノ酸を蛋白源とし、これに脂肪、炭水化物、
ミネラル、ビタミン等の栄養素を含有させて解決するこ
とができた。As a result of our research in search of an easy-to-drink nutritional preparation for histidinemic infants, we found that natural milk whey protein and amino acids are the protein sources, and fat, carbohydrate, and
We were able to solve this problem by adding nutrients such as minerals and vitamins.
本発明は、蛋白源として下記組成から成る窒素化合物及
び脂肪、炭水化物、ミネラル、ビタミンからなるヒスチ
ジン血症乳幼児用栄養調製物である。The present invention is a nutritional preparation for infants with histidinemia consisting of a nitrogen compound having the following composition as a protein source, and fat, carbohydrate, minerals, and vitamins.
重量%
牛乳ホエー蛋白質 25.O〜30.OL−
インロイシン 6.2〜4.2L−
ロイシン Z6〜10.1L−
リジン 6.4〜85L−メチ
オニン 2.2〜2.9(3)
L−シスチン 2.1〜2.8
L−フェニールアラニン 60〜69L−チ
ロシン 4,7〜62L−スレ
オニン 2.5〜3.6L−トリ
プトファン 1.6〜2.1L−バリ
ン 3.9〜52L−アルギニン
4,3〜56L−アラニン
6.1〜4.1L−アスパラギン酸
35〜4.7L−グルタミン酸
7.9〜10.4L−グリンン
6,7〜4.9L−プロリン
4,5〜5.7L−ヤリ7
2.4〜3.1本発明においては自然の
牛乳ホエー蛋白質を主体アミノ酸源とし、さらに必要な
アミノ酸を添加し、栄養調製物中のヒスチジン含量を相
対的に低減せしめたヒスチジン血症乳幼児用栄養調製物
となっている。Weight% Milk whey protein 25. O~30. OL-
Inleucine 6.2-4.2L-
Leucine Z6-10.1L-
Lysine 6.4-85 L-methionine 2.2-2.9 (3) L-cystine 2.1-2.8
L-phenylalanine 60-69L-tyrosine 4,7-62L-threonine 2.5-3.6L-tryptophan 1.6-2.1L-valine 3.9-52L-arginine
4,3-56L-alanine
6.1-4.1L-aspartic acid
35-4.7L-glutamic acid
7.9~10.4L-Green
6,7-4.9L-proline
4,5~5.7L-Spear 7
2.4-3.1 The present invention provides a nutrition for infants with histidinemia, which uses natural milk whey protein as the main amino acid source, further adds necessary amino acids, and relatively reduces the histidine content in the nutritional preparation. It is a preparation.
上記の如く混合して調製した粉末状の製剤に含まれるヒ
スチジン含量は50〜100mfiI/1oog(4)
製剤で、通常の製剤中の含量に比べてかなり低く、約1
15〜1/10のヒスチジン量に過ぎない。したがって
、ヒスチジンの摂取量が制限でき、同時に他の必要なア
ミノ酸も自然の形で摂取でき、異臭や苦味がないので飲
みやすく、乳幼児でも容易に飲用できるようになったも
のである。The histidine content in the powdered preparation prepared by mixing as described above is 50 to 100 mfiI/1oog (4), which is considerably lower than the content in normal preparations, and about 1
The amount of histidine is only 1/15 to 1/10. Therefore, the amount of histidine ingested can be restricted, and at the same time, other necessary amino acids can be ingested in a natural form, and since there is no off-odor or bitter taste, it is easy to drink, and even infants can easily drink it.
本発明の栄養調製物中の蛋白質とアミノ酸からなる窒素
化合物含量は、13〜17重量係程度が適当である。The content of nitrogen compounds consisting of protein and amino acids in the nutritional preparation of the present invention is suitably about 13 to 17% by weight.
また、本発明に用いる炭水化物としては、消化吸収性の
良い可溶性多糖類(デキス) IJン)、乳糖、蔗糖等
直ちにエネルギー源となるものを組み合わせて使用し、
その使用量は55〜70重量%程度である。また、脂肪
としては、サフラワー油、コーン油、大豆油、ヤシ油等
の植物性油、ラード等の動物性油およびMCT油(Mi
dium−Chain −Triglyceride)
等が使用され、その使用量は15〜25重量−程度であ
る。ビタミンとしてはFAO/WHO合同食品規格計画
Codex食品規格委員会CAC/R872−1976
乳児用調製乳の勧告国際規格(以下勧告規格という)を
満たせるようにビタミンA、B1、B7、BいB111
、CL D、 B、 K1、パントテン酸、ニコチン酸
、葉酸、コリン、ビオチン、イノジット等が使用される
。ビタミン類の全体の使用量は、0.1重量−程度であ
る。ミネラルとしては、勧告規格を満たせるように、硫
酸第一鉄、コハク酸クエン酸鉄ナトリウム等の鉄塩、硫
酸銅、グルコン酸銅等の銅塩、硫酸亜鉛、塩化亜鉛等の
亜鉛塩および塩化物、酢酸マンガン等のマンガン塩、酢
酸コバルト等のコバルト塩、ヨウ化カリウム、リン酸−
カリウム等のヨウ化物、カリウム塩およびリン酸塩、塩
化マグネシウム等のマグネシウムおよび塩化物、塩化ナ
トリウム等のナトリウム塩および塩化物、リン酸−ナト
リウム等のリン酸塩およびナトリウム塩、炭酸カルシウ
ム等のカルシウム塩が使用される、ミネラル全体の使用
量は2〜5重i−程度である。In addition, as the carbohydrates used in the present invention, carbohydrates that are easily digestible and absorbable, such as soluble polysaccharides (dex), lactose, and sucrose, are used in combination as an immediate energy source.
The amount used is about 55 to 70% by weight. Fats include vegetable oils such as safflower oil, corn oil, soybean oil, and coconut oil, animal oils such as lard, and MCT oil (Mi
dium-Chain-Triglyceride)
etc. are used, and the amount used is about 15 to 25% by weight. As for vitamins, FAO/WHO Joint Food Standards Program Codex Food Standards Committee CAC/R872-1976
Vitamins A, B1, B7, and B111 are added to meet the recommended international standards for infant formula (hereinafter referred to as the Recommended Standards).
, CLD, B, K1, pantothenic acid, nicotinic acid, folic acid, choline, biotin, inosit, etc. are used. The total amount of vitamins used is about 0.1 weight. Minerals include iron salts such as ferrous sulfate and sodium iron citrate succinate, copper salts such as copper sulfate and copper gluconate, zinc salts and chlorides such as zinc sulfate and zinc chloride, in order to meet the recommended standards. , manganese salts such as manganese acetate, cobalt salts such as cobalt acetate, potassium iodide, phosphoric acid -
Iodides such as potassium, potassium salts and phosphates, magnesium and chlorides such as magnesium chloride, sodium salts and chlorides such as sodium chloride, phosphates and sodium salts such as sodium phosphate, calcium such as calcium carbonate The amount of salt used in total minerals is about 2 to 5 times i-.
以上の各種組成物は均一に混合し、粉末状に調製され、
ヒスチジン血症乳幼児用栄養調製物とされる。The above various compositions are mixed uniformly and prepared into powder form,
It is said to be a nutritional preparation for infants with histidinemia.
本発明のヒスチジン血症乳幼児用栄養調製物は上記各成
分を粉末状に混合調製されており、投与時には標準で1
5 tI)W/Vの濃度に水に溶かして投与される。投
与は経口投与、経腸投与のいずれでもよい。The nutritional preparation for infants with histidinemia of the present invention is prepared by mixing the above-mentioned components in powder form, and at the time of administration, the standard
Administered in water at a concentration of 5 tI) W/V. Administration may be either oral or enteral administration.
本発明のヒスチジン血症乳幼児用栄養調製物は、乳幼児
のヒスチジン血症の治療に、ヒスチジンを全く含まない
調製物や牛乳等と独立にまたは混合してヒスチジン含量
を随意調整し2て使用できるものである。The nutritional preparation for infants with histidinemia of the present invention can be used for the treatment of histidinemia in infants, either independently or in combination with a preparation containing no histidine, milk, etc., after adjusting the histidine content as desired. It is.
次に本発明の実施例を示す。Next, examples of the present invention will be shown.
実施例
牛乳ホエー蛋白質 458gラード
IO,24gパーム油
1.43g大豆油
6.14gヤシ油
2.669レシチン
0.200.li+乳糖 45.23g
デキストリン 14.10g(7
)
ニコチン酸アミド9 6,6■リボフラ
ビン(V、B、) 1.0■イノジ
ツト 1B、Orvジアノコバラ
ミン(V、 B、21 5.0μgビタミ
ンAとビタミンDの混合物 6.θ■ビタミ
ンに+ 110.0μgビタミ
ンg 6.6m9モノグリ
セリド 279.0m9シユガーエ
ステル 555.6■塩酸チアミン
(■。B、+ 0.72■塩酸ピリ
ドキシン(V、B6) 0.4シψL−
7スコルビン酸(VC) 55.0rn9
葉酸 0.24m9
パントテン酸カルシウム 2.4 m
9グリセロリン酸カルシウム 1.4B
2.!i’炭酸カルシウム 254
.8rvクエン酸コハク酸鉄ナトリウム
80.0■ヨウ化カリウム
0,11■炭酸カリウム 81
1.9m9塩化マグネシウム六水塩 25
0.8■(8)
塩化ナトリウム 552.′51v硫酸
銅五水塩 1.552m9塩化亜
鉛 5.131111i1酢
酸マンガン四水塩 0.669〜酢
酸コバルト四水塩 0.211■以
上をよく混合し、ヒスチジン血症乳幼児用栄養調製物と
した。上記調製物は、15チW/Vで40℃位の水に溶
解し、経口的または経腸的にヒスチジン血症乳幼児に投
与される。Example milk whey protein 458g lard
IO, 24g palm oil
1.43g soybean oil
6.14g coconut oil
2.669 lecithin
0.200. li + lactose 45.23g dextrin 14.10g (7
) Nicotinic acid amide 9 6,6 ■ Riboflavin (V, B, ) 1.0 ■ Inojitsu 1B, Orv Dianocobalamin (V, B, 21 5.0 μg Mixture of vitamin A and vitamin D 6. θ ■ Vitamin + 110.0μg Vitamin g 6.6m9 Monoglyceride 279.0m9 Sugar ester 555.6■ Thiamine hydrochloride (■.B, + 0.72■ Pyridoxine hydrochloride (V, B6) 0.4shiψL-
7 Scorbic acid (VC) 55.0rn9
Folic acid 0.24 m9 Calcium pantothenate 2.4 m
9 Calcium glycerophosphate 1.4B
2. ! i' Calcium carbonate 254
.. 8rv Sodium iron succinate citrate
80.0 ■ Potassium iodide
0,11 ■ Potassium carbonate 81
1.9m9 Magnesium chloride hexahydrate 25
0.8■(8) Sodium chloride 552. '51v Copper sulfate pentahydrate 1.552m9 Zinc chloride 5.131111i1 Manganese acetate tetrahydrate 0.669 to cobalt acetate tetrahydrate 0.211cm or more were thoroughly mixed to prepare a nutritional preparation for infants with histidinemia. The above preparation is dissolved in water at about 40° C. at 15 cm W/V and administered orally or enterally to histidinemic infants.
代理人 弁理士 戸 1)親 男Agent Patent Attorney 1) Parent Male
Claims (1)
水化物、ミネラル、゛ビタミンからなるヒスチジン血症
乳幼児用栄養調製物。 重量% 牛乳ホエー蛋白質 □ 25.0〜50.OL−
インロイシン 3,2〜4.2L−ロ
イシン Z6〜101L−リジ
ン ′6.4〜8.5L−メチオニン
2.2〜2.9L−シスチン
2.1〜2.8L−フェニールアラニン
6.0〜 ′5.9L−チロシン
・ ・ 47〜6.2L−スレオニン
2,5〜6.3L−)リプトファン
1.6に 2.1L−バリン
3.9〜5,2L−アルギニン
4.5〜5,6L−アラニア
61〜4.1L−アスパラギン酸
55〜4,7L−グルタミン酸゛
Z9〜10.4L−グリシン
6.7〜4.9L−プロ9/
43〜5,7L−セリン 2
.4〜31[Scope of Claims] A nutritional preparation for infants with histidinemia, consisting of a nitrogen compound as a protein source, and fat, carbohydrate, minerals, and vitamins. Weight% Milk whey protein □ 25.0-50. OL-
Inleucine 3,2-4.2L-leucine Z6-101L-lysine '6.4-8.5L-methionine
2.2-2.9L-cystine
2.1~2.8L-Phenylalanine 6.0~'5.9L-Tyrosine
・ ・ 47-6.2L-threonine
2,5-6.3L-)Liptophan
1.6 to 2.1L-valine
3.9-5,2L-arginine
4.5-5,6L-Alania
61-4.1L-aspartic acid
55-4,7L-glutamic acid
Z9-10.4L-glycine
6.7-4.9L-Pro 9/
43-5,7L-serine 2
.. 4-31
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57098516A JPS58216122A (en) | 1982-06-10 | 1982-06-10 | Nutrient product for infant of histidinemia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57098516A JPS58216122A (en) | 1982-06-10 | 1982-06-10 | Nutrient product for infant of histidinemia |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS58216122A true JPS58216122A (en) | 1983-12-15 |
Family
ID=14221810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP57098516A Pending JPS58216122A (en) | 1982-06-10 | 1982-06-10 | Nutrient product for infant of histidinemia |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS58216122A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6049764A (en) * | 1983-08-29 | 1985-03-19 | Ajinomoto Co Inc | Food composition |
JPS60186261A (en) * | 1984-03-06 | 1985-09-21 | Ajinomoto Co Inc | Solid food composition |
JPS6463358A (en) * | 1987-05-29 | 1989-03-09 | Union Ind I Agurooganadera Sa | Nucleotide and/or nutritious product containing rich nucleotide for children and adults and method for manufacture thereof |
US5994322A (en) * | 1990-08-08 | 1999-11-30 | Kewpie Kabusiki Kaisya | Compositions for preventing dementia |
-
1982
- 1982-06-10 JP JP57098516A patent/JPS58216122A/en active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6049764A (en) * | 1983-08-29 | 1985-03-19 | Ajinomoto Co Inc | Food composition |
JPH0368665B2 (en) * | 1983-08-29 | 1991-10-29 | Ajinomoto Kk | |
JPS60186261A (en) * | 1984-03-06 | 1985-09-21 | Ajinomoto Co Inc | Solid food composition |
JPH0458304B2 (en) * | 1984-03-06 | 1992-09-17 | Ajinomoto Kk | |
JPS6463358A (en) * | 1987-05-29 | 1989-03-09 | Union Ind I Agurooganadera Sa | Nucleotide and/or nutritious product containing rich nucleotide for children and adults and method for manufacture thereof |
US5994322A (en) * | 1990-08-08 | 1999-11-30 | Kewpie Kabusiki Kaisya | Compositions for preventing dementia |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0034034B1 (en) | Nutrient composition | |
US5292538A (en) | Improved sustained energy and anabolic composition and method of making | |
US5270297A (en) | Endurance and rehydration composition | |
US6667063B2 (en) | Nutritional or therapeutic supplement and method | |
US4994283A (en) | Iron-calcium mineral supplements with enhanced bioavailability | |
US5118513A (en) | Method for enhancing bioavailability of iron-calcium mineral supplements | |
US4303692A (en) | Infant milk formula | |
JP2983503B2 (en) | Iron-calcium mineral supplement with high bioavailability | |
EP0891719A1 (en) | Nutritional composition containing methionine | |
JPH0671414B2 (en) | Iron mineral supplement | |
IE61394B1 (en) | Calcium-iron mineral supplements | |
CA2821725A1 (en) | Nutritional products comprising calcium beta-hydroxy-beta methylbutyrate and conjugated linoleic acid | |
IE860240L (en) | Enteral nutritional hypoallergenic compositions | |
CA2097196C (en) | Enteral preparation for cancer therapy | |
Theuer et al. | Effect of processing on availability of iron salts in liquid infant formula products. Experimental soy isolate formulas | |
US4419369A (en) | Protein mineral dietary module | |
US4220667A (en) | Zinc containing condiments | |
JP2920434B2 (en) | Food and drink containing calcium and dietary fiber and method for producing the same | |
JPS58216122A (en) | Nutrient product for infant of histidinemia | |
JPH0335896B2 (en) | ||
JP2002142720A (en) | Nutritional composition | |
JPS595111A (en) | Prepared nutritious substance for infant with phenylketonuria | |
JPH0558889A (en) | Fat amino acid powder and powdery nutritious composition | |
JPS5953429A (en) | Nutritive prepared substance for maple syrup urine disease of infants | |
US2860051A (en) | Food composition |